@article{Vaidya2019,title = {6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial},journal = {The Lancet},year = {2019},volume = {393},number = {10191},pages = {2599-2612},author = {Earl, H.M. and Hiller, L. and Vallier, A.-L. and Loi, S. and McAdam, K. and Hughes-Davies, L. and Harnett, A.N. and Ah-See, M.-L. and Simcock, R. and Rea, D. and Raj, S. and Woodings, P. and Harries, M. and Howe, D. and Raynes, K. and Higgins, H.B. and Wilcox, M. and Plummer, C. and Mansi, J. and Gounaris, I. and Mahler-Araujo, B. and Provenzano, E. and Chhabra, A. and Abraham, J.E. and Caldas, C. and Hall, P.S. and McCabe, C. and Hulme, C. and Miles, D. and Wardley, A.M. and Cameron, D.A. and Dunn, J.A. and Agarwal, R. and Algurafi, H. and Allerton, R. and Archer, C. and Armstrong, A. and Bale, C. and Barraclough, L. and Barthakur, U. and Bedi, C. and Benstead, K. and Bloomfield, D. and Bowen, R. and Bradley, C. and Brown, J. and Butt, M. and Churn, M. and Cleator, S. and Cliff, J. and Crellin, P. and Daly, M. and De Silva-Minor, S. and Dhadda, A. and Din, O. and Down, S. and Earl, H. and Eaton, D. and Eichholz, A. and Epurescu, D. and Goh, C. and Goodman, A. and Grieve, R. and Hadaki, M. and Harper-Wynne, C. and Hayward, L. and Humphreys, A. and Innes, H. and Jafri, M. and Jegannathen, A. and Kelleher, M. and Kristeleit, H. and Lee, D. and Lupton, S. and MacGregor, C. and Malik, Z. and Marshall, J. and McGolick, T. and Mehra, R. and Mithal, N. and Moss, C. and Moss, A. and Mukesh, M. and Neal, A. and Nelmes, D. and Neville-Webbe, H. and Newby, J. and O{'}Reilly, S. and Ostler, P. and Persic, M. and Pettit, L. and Raja, F. and Reed, C. and Rigg, A. and Roe, H. and Shah, N. and Simmonds, P. and Sims, E. and Smith, S. and Storey, N. and Taylor, W. and Thanvi, N. and Tipples, K. and Vaidya, J. and Varughese, M. and Vinayan, A. and Walji, N. and Waters, S. and Wright, K. and Yahya, S.}}